Form 4: Indivior Legal Chief's Stock Vesting & Tax Sale

Indivior Pharmaceuticals' Chief Legal Officer, Jeffrey W. Burris, acquired 79,893 shares through PSU vesting and sold 36,032 shares for tax obligations.

Summary

• Jeffrey W. Burris, Chief Legal Officer of Indivior Pharmaceuticals, Inc., reported transactions on March 3, 2026.
• 79,893 shares of common stock were acquired due to the vesting of performance stock units (PSUs).
• The PSUs, granted on March 3, 2023, vested at 76.6% of the target amount of 104,300 units.
• 36,032 shares were subsequently disposed of at a price of $31.98 per share to cover tax withholding obligations related to the PSU vesting.
• Following these transactions, Burris directly beneficially owns 71,518 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the successful vesting of performance-based equity awards, albeit not at 100%, and a routine tax-related share disposition.

Positives

• Vesting of performance stock units indicates that performance conditions were met, albeit at 76.6% of the target.
• The Chief Legal Officer's continued ownership of a significant number of shares (71,518) aligns his interests with shareholders.

Negatives

• A portion of the vested shares (36,032) was immediately sold to cover tax liabilities, which is a common practice but reduces direct ownership.
• The PSUs vested at 76.6% of the target, implying that not all performance conditions were fully met to achieve 100% vesting.

Risks

• Future performance conditions for equity awards may not be fully met, potentially impacting executive compensation and retention.

Future Outlook

This Form 4 does not contain forward-looking statements or guidance; it reports past insider transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, providing transparency into executive stock ownership changes. These transactions, particularly those related to equity award vesting and tax sales, are common and generally not indicative of a change in management's fundamental view of the company's prospects, but rather a standard part of executive compensation plans.

Comparison to Industry Standards

• This filing details a standard executive compensation event involving performance stock unit vesting and subsequent share sales for tax purposes.
• Such events are common across publicly traded companies, particularly in the pharmaceutical sector, where long-term incentive plans often include performance-based equity awards.
• For example, similar vesting and tax-related sales are observed in filings from executives at companies like Pfizer, Johnson & Johnson, and Merck, where equity compensation is a significant component of total remuneration.
• The 76.6% vesting rate suggests performance metrics were met, but not fully exceeded, which is within typical industry ranges for performance-based awards.

Related Party Transactions

• The transaction involves an executive (Jeffrey W. Burris) and the company (Indivior Pharmaceuticals, Inc.) as part of an established compensation plan.

Stakeholder Impact

• Shareholders: The vesting of PSUs indicates that the company met certain performance targets, which could be viewed positively. The sale of shares for tax purposes is a routine event and does not necessarily signal a lack of confidence.
• Employees: The successful vesting of executive equity awards can reinforce the effectiveness of the company's compensation structure.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions related to executive compensation, specifically the vesting of performance stock units and subsequent sale of shares for tax obligations. It does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions are expected and do not signal a significant shift in insider sentiment or company prospects. Therefore, a "hold" recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Indivior Pharmaceuticals, INDV, Form 4, Insider Trading, Stock Vesting, Performance Stock Units, Executive Compensation, Jeffrey W Burris, Chief Legal Officer, Share Ownership